Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
Authors:
- Ajay K. SinghASAjay K. Singh
- Kevin CarrollKCKevin Carroll
- Vlado PerkovicVPVlado Perkovic
- Scott SolomonSSScott Solomon
- Vivekanand JhaVJVivekanand Jha
- Kirsten L. JohansenKJKirsten L. Johansen
- Renato D. LopesRLRenato D. Lopes
- Iain C. MacdougallIMIain C. Macdougall
- Gregorio T. ObradorGOGregorio T. Obrador
- Sushrut S. WaikarSWSushrut S. Waikar
- Christoph WannerCWChristoph Wanner
- David C. WheelerDWDavid C. Wheeler
Top Cited Papers
- 16 December 2021
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (25) , 2325-2335
Abstract
Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse events. Several trials have suggested that hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in increasing hemoglobin levels. In this randomized, open-label, phase 3 trial, we assigned patients with CKD who were undergoing dialysis and who had a hemoglobin level of 8.0 to 11.5 g per deciliter to receive an oral HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were receiving hemodialysis or darbepoetin alfa if they were receiving peritoneal dialysis). The two primary outcomes were the mean change in the hemoglobin level from baseline to weeks 28 through 52 (noninferiority margin, −0.75 g per deciliter) and the first occurrence of a major adverse cardiovascular event (a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke), with a noninferiority margin of 1.25. A total of 2964 patients underwent randomization. The mean (±SD) baseline hemoglobin level was 10.4±1.0 g per deciliter overall. The mean (±SE) change in the hemoglobin level from baseline to weeks 28 through 52 was 0.28±0.02 g per deciliter in the daprodustat group and 0.10±0.02 g per deciliter in the ESA group (difference, 0.18 g per deciliter; 95% confidence interval [CI], 0.12 to 0.24), which met the prespecified noninferiority margin of −0.75 g per deciliter. During a median follow-up of 2.5 years, a major adverse cardiovascular event occurred in 374 of 1487 patients (25.2%) in the daprodustat group and in 394 of 1477 (26.7%) in the ESA group (hazard ratio, 0.93; 95% CI, 0.81 to 1.07), which also met the prespecified noninferiority margin for daprodustat. The percentages of patients with other adverse events were similar in the two groups. Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-D ClinicalTrials.gov number, NCT02879305.)Keywords
Funding Information
- GlaxoSmithKline Australia (N/A)
This publication has 17 references indexed in Scilit:
- Anaemia in kidney disease: harnessing hypoxia responses for therapyNature Reviews Nephrology, 2015
- Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesisJournal of Clinical Investigation, 2012
- Mechanisms of Anemia in CKDJournal of the American Society of Nephrology, 2012
- Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRDJournal of the American Society of Nephrology, 2010
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrology Dialysis Transplantation, 2004
- The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammationJournal of Clinical Investigation, 2002
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998